STARD5

Across TCGA pan-cancer cohorts, STARD5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STARD5 data layer compared with 29 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STARD5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated STARD5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where STARD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.946	0.670	.005	36	view →
HNSC	DFS	Median	All	0.736	0.547	.013	31	view →
PDAC	OS	Tertile	All	0.557	0.299	.007	29	view →
GBM	DFS	Median	All	0.236	0.446	<.001	21	view →
LUAD	DFS	Tertile	II,III,IV	0.893	0.198	.002	9	view →
UCEC	DFS	Median	All	0.934	1.000	.019	8	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STARD5–CCRCC (OS)

Open the CCRCC breakdown →